Diagnostic Imaging Centers of Texas is adding VoxNeuro's FDA-cleared EEG-based Cognitive Function Neuroimaging to its MRI and CT services, pairing structural scans with an objective measure of how the brain responds during attention and memory tasks. The event-related potential analysis is completed in a single visit and cleared for prescription use in adults aged 18 to 70, without providing diagnosis or clinical interpretation. No outcome data has been published on whether the test alters treatment decisions or recovery trajectories.
Key Points
- EEG event-related potentials measure brain function alongside structural MRI and CT
- FDA 510(k) clearance covers prescription use, adults 18 to 70
- No published data yet on treatment impact or recovery outcomes
Longevity Analysis
Brain aging has long suffered from a measurement gap: anatomy is easy to image, performance is not. A short, repeatable test that quantifies how quickly and accurately the brain processes auditory and visual input offers a functional baseline that can be tracked across decades, rather than waiting for cognitive decline to surface as symptoms. Deployment through a high-volume imaging network also builds the longitudinal dataset needed to establish what normal trajectories of neural signaling look like — though the current clearance is scoped to injury recovery, and its value in healthy aging remains an open research question.
Original published by Longevity.Technology, by Kyle Umipig.